Close Menu

NEW YORK (GenomeWeb) – Shares of Biocept spiked nearly 90 percent on Monday after the company announced that it had commercially launched its Target Selector NGS Lung Panel assay.

In afternoon trading on Nasdaq, the San Diego-based company's shares were trading at $1.58 compared to Friday's closing price of $.82, as trading volume increased more than 30-fold to about 66 million shares from an average daily volume of 1.9 million shares.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jul
23
Sponsored by
Qiagen

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients. 

Jul
25

This webinar will discuss the evolution of fetal aneuploidy screening and the most recent evidence around the implementation of prenatal cell-free DNA testing in clinical practice.